NCT03037385 · OUTCOME
Phase 1 and Phase 2: CBR in RET-mutation MTC Participants With Specific RET Gene Status
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors · Source last updated 2025-05-31
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- percentage of participants
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Up to approximately 79.8 months
What was measured
Oncogenic RET activation has been implicated as a driver in MTC. These rearrangements typically produce chimeric transcripts that encode a fusion protein consisting of the RET kinase domain coupled to a protein with a dimerization domain (e.g., M918T, cysteine rich domain, V804X). RET genotypes were determined by local testing and/or central analysis of ctDNA. CBR was assessed in participants having specific RET rearrangements. CBR was defined as the percentage of participants with a confirmed CR or PR, or SD which has been lasting at least 16 weeks (i.e. 4 cycles if 28 days are in one cycle) from the first dose date. CR and PR were defined per RECIST as outlined in the description for OM 3. SD was defined as neither sufficient shrinkage to qualify for CR or PR nor sufficient increase to qualify for PD. PD was defined as at least a 20% increase in SOD of target lesions, taking as reference the smallest SOD on study (including baseline).
Analysis population: RET-altered measurable disease population included participants in the efficacy population who have measurable (target) disease per RECIST v1.1, at baseline according to BICR and sufficient evidence of a RET alteration. As prespecified in the SAP, Phase 1 participants treated at 400 mg QD are pooled with Phase 2 participants for efficacy analysis. Number analyzed is the number of participants with the specified mutation.
Groups in this outcome
RET-mutation MTC With Prior Cabozantinib and/or Vandetanib Treatment
Participants who had RET- mutation positive MTC previously treated with either cabozantinib and/or vandetanib therapies received pralsetinib, 400 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons.
RET-mutation MTC With No Prior Cabozantinib or Vandetanib Treatment
Participants who had RET- mutation positive MTC not previously treated with cabozantinib or vandetanib therapies received pralsetinib, 400 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons.
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
| Group | Source count |
|---|
| RET-mutation MTC With Prior Cabozantinib and/or Vandetanib Treatment | 60 |
|---|
| RET-mutation MTC With No Prior Cabozantinib or Vandetanib Treatment | 72 |
|---|
Reported measurements
M918T
Analysis denominator · Participants
| Group | Source count |
|---|
| RET-mutation MTC With Prior Cabozantinib and/or Vandetanib Treatment | 41 |
|---|
| RET-mutation MTC With No Prior Cabozantinib or Vandetanib Treatment | 43 |
|---|
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval| Group | Value | Spread | Lower | Upper | Comment |
|---|
| RET-mutation MTC With Prior Cabozantinib and/or Vandetanib Treatment | 78.0 | Not reported | 62.4 | 89.4 | Not reported |
|---|
| RET-mutation MTC With No Prior Cabozantinib or Vandetanib Treatment | 86.0 | Not reported | 72.1 | 94.7 | Not reported |
|---|
Cysteine Rich Domain
Analysis denominator · Participants
| Group | Source count |
|---|
| RET-mutation MTC With Prior Cabozantinib and/or Vandetanib Treatment | 13 |
|---|
| RET-mutation MTC With No Prior Cabozantinib or Vandetanib Treatment | 25 |
|---|
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval| Group | Value | Spread | Lower | Upper | Comment |
|---|
| RET-mutation MTC With Prior Cabozantinib and/or Vandetanib Treatment | 76.9 | Not reported | 46.2 | 95.0 | Not reported |
|---|
| RET-mutation MTC With No Prior Cabozantinib or Vandetanib Treatment | 96.0 | Not reported | 79.6 | 99.9 | Not reported |
|---|
V804X
Analysis denominator · Participants
| Group | Source count |
|---|
| RET-mutation MTC With Prior Cabozantinib and/or Vandetanib Treatment | 2 |
|---|
| RET-mutation MTC With No Prior Cabozantinib or Vandetanib Treatment | 1 |
|---|
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval| Group | Value | Spread | Lower | Upper | Comment |
|---|
| RET-mutation MTC With Prior Cabozantinib and/or Vandetanib Treatment | 100 | Not reported | 15.8 | 100 | Not reported |
|---|
| RET-mutation MTC With No Prior Cabozantinib or Vandetanib Treatment | 100 | Not reported | 2.5 | 100 | Not reported |
|---|
Other
Analysis denominator · Participants
| Group | Source count |
|---|
| RET-mutation MTC With Prior Cabozantinib and/or Vandetanib Treatment | 4 |
|---|
| RET-mutation MTC With No Prior Cabozantinib or Vandetanib Treatment | 3 |
|---|
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval| Group | Value | Spread | Lower | Upper | Comment |
|---|
| RET-mutation MTC With Prior Cabozantinib and/or Vandetanib Treatment | 100 | Not reported | 39.8 | 100 | Not reported |
|---|
| RET-mutation MTC With No Prior Cabozantinib or Vandetanib Treatment | 100 | Not reported | 29.2 | 100 | Not reported |
|---|
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 62.4
- upper Limit
- 89.4
- value
- 78.0
- group Id
- OG001
- lower Limit
- 72.1
- upper Limit
- 94.7
- value
- 86.0
- denoms
- counts
- group Id
- OG000
- value
- 41
- group Id
- OG001
- value
- 43
- units
- Participants
- title
- M918T
- categories
- measurements
- group Id
- OG000
- lower Limit
- 46.2
- upper Limit
- 95.0
- value
- 76.9
- group Id
- OG001
- lower Limit
- 79.6
- upper Limit
- 99.9
- value
- 96.0
- denoms
- counts
- group Id
- OG000
- value
- 13
- group Id
- OG001
- value
- 25
- units
- Participants
- title
- Cysteine Rich Domain
- categories
- measurements
- group Id
- OG000
- lower Limit
- 15.8
- upper Limit
- 100
- value
- 100
- group Id
- OG001
- lower Limit
- 2.5
- upper Limit
- 100
- value
- 100
- denoms
- counts
- group Id
- OG000
- value
- 2
- group Id
- OG001
- value
- 1
- units
- Participants
- title
- V804X
- categories
- measurements
- group Id
- OG000
- lower Limit
- 39.8
- upper Limit
- 100
- value
- 100
- group Id
- OG001
- lower Limit
- 29.2
- upper Limit
- 100
- value
- 100
- denoms
- counts
- group Id
- OG000
- value
- 4
- group Id
- OG001
- value
- 3
- units
- Participants
- title
- Other
- denoms
- counts
- group Id
- OG000
- value
- 60
- group Id
- OG001
- value
- 72
- units
- Participants
- description
- Oncogenic RET activation has been implicated as a driver in MTC. These rearrangements typically produce chimeric transcripts that encode a fusion protein consisting of the RET kinase domain coupled to a protein with a dimerization domain (e.g., M918T, cysteine rich domain, V804X). RET genotypes were determined by local testing and/or central analysis of ctDNA. CBR was assessed in participants having specific RET rearrangements. CBR was defined as the percentage of participants with a confirmed CR or PR, or SD which has been lasting at least 16 weeks (i.e. 4 cycles if 28 days are in one cycle) from the first dose date. CR and PR were defined per RECIST as outlined in the description for OM 3. SD was defined as neither sufficient shrinkage to qualify for CR or PR nor sufficient increase to qualify for PD. PD was defined as at least a 20% increase in SOD of target lesions, taking as reference the smallest SOD on study (including baseline).
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Participants who had RET- mutation positive MTC previously treated with either cabozantinib and/or vandetanib therapies received pralsetinib, 400 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons.
- id
- OG000
- title
- RET-mutation MTC With Prior Cabozantinib and/or Vandetanib Treatment
- description
- Participants who had RET- mutation positive MTC not previously treated with cabozantinib or vandetanib therapies received pralsetinib, 400 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons.
- id
- OG001
- title
- RET-mutation MTC With No Prior Cabozantinib or Vandetanib Treatment
- param Type
- NUMBER
- population Description
- RET-altered measurable disease population included participants in the efficacy population who have measurable (target) disease per RECIST v1.1, at baseline according to BICR and sufficient evidence of a RET alteration. As prespecified in the SAP, Phase 1 participants treated at 400 mg QD are pooled with Phase 2 participants for efficacy analysis. Number analyzed is the number of participants with the specified mutation.
- reporting Status
- POSTED
- time Frame
- Up to approximately 79.8 months
- title
- Phase 1 and Phase 2: CBR in RET-mutation MTC Participants With Specific RET Gene Status
- type
- SECONDARY
- unit Of Measure
- percentage of participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle